About

About nanologica

Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. We have an expertise in chromatography and are one of the world-leaders in developing nanoporous silica particles for purification by chromatography.

Through a proprietary manufacturing method, we can precisely control the shape, size, porosity, and surface properties of silica particles, enabling the creation of world-class products that can purify more effectively and that last longer. This can streamline production processes and significantly reduce production costs and increase productivity for pharmaceutical manufacturers.

Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. 

Silica particles are visible as a fine white powder. The particles are spherical, have a smooth surface, and are fully porous creating a large surface area.


Vision

Better and cheaper medicine to a larger number of patients.

Mission

           We aim to make diabetes and obesity medicines available to more patients by providing products
that can lower the manufacturing costs of these drugs.

Objectives

              Nanologica works to establish a rapidly growing, sustainable and profitable business within                          chromatography by providing products for the purification of substances in pharmaceutical production. 
Main focus is peptide-based drugs such as insulin and GLP-1 analogues. 


Chromatography is a widely used technique for separating components in a mixture. Nanologica is active mainly in preparative chromatography, which is used by pharmaceutical manufacturers for the purification of drugs during production. Our products have been especially developed for the purification of peptide drugs such as insulin and GLP-1 analogues.

Sales are conducted directly and together with partners on all major markets – India, China, the US, and Europe.

Nanologica has a pilot plant at the headquarters in Södertälje. This is where development of new products, customer support in the form of application support and method development takes place, as well as production of silica on a smaller scale. For large-scale production, the company works together with partners. Large-scale production of silica takes place at a contract manufacturer in the UK in a GMP-certified factory with multi-ton scale capacity.

Nanologica’s share (NICA) is listed on Nasdaq Stockholm Main Market since 2022.